In the relentless pursuit of advancing cancer treatment, a groundbreaking study has emerged from the Mass General Brigham Cancer Institute, shedding light on the long-term efficacy of pralsetinib, an FDA-approved targeted therapy for non-small cell lung cancers (NSCLCs) driven by RET gene fusions. RET fusions, a critical genetic alteration found in a subset of NSCLC patients, have been identified as potent oncogenic drivers, catalyzing tumor growth and progression. Historically, the prognosis for patients harboring these genetic rearrangements was dismal, with median survival rates ranging merely from four to eleven months. However, new evidence furnished by an extensive 42-month follow-up in a phase 1/2 clinical trial now heralds a promising therapeutic frontier.
This clinical investigation, denominated the ARROW study, was designed to rigorously evaluate pralsetinib’s long-term clinical benefits and safety profile. Unlike conventional chemotherapies with broad cytotoxic effects, pralsetinib specifically targets RET kinase activity, disrupting tumor cell signaling cascades pivotal for cancer cell survival and proliferation. The study embraced a cohort of 281 patients diagnosed with advanced or metastatic RET fusion-positive NSCLCs, including subgroups that were treatment-naive, those who had undergone previous chemotherapy, and individuals with brain metastases. This extensive patient population allowed for a comprehensive assessment of the drug’s efficacy across diverse clinical landscapes.
What distinguishes pralsetinib from earlier therapeutic approaches is its precision in intercepting the aberrant gene fusion pathways. RET fusions arise predominantly with partner genes such as CCDC6 and KIF5B, resulting in constitutively active chimeric proteins that drive malignant transformation. Intriguingly, the study revealed variation in therapeutic durability based on fusion partner type; patients exhibiting the CCDC6-RET fusion demonstrated a striking median duration of response stretching nearly four years, a stark contrast to the markedly shorter 13.1 months observed in those with KIF5B-RET fusions. This nuanced understanding underscores the complex biology underpinning RET-driven oncogenesis and hints at the potential for fusion-specific therapeutic strategies.
The response rates observed were equally compelling. Untreated patients witnessed an impressive overall response rate (ORR) of 78%, whereas individuals with prior chemotherapy exposure still achieved 63%. The efficacy extended into the challenging realm of brain metastases, a common complication in advanced lung cancer, where a 73% ORR was recorded. These figures not only emphasize pralsetinib’s robust antitumor activity but also its ability to penetrate the blood-brain barrier, a notorious obstacle in oncology drug development. Such advances accentuate the shifting paradigm in lung cancer treatment, tilting towards personalized medicine grounded in molecular pathology.
Closely scrutinizing the safety profile, pralsetinib demonstrated generally manageable toxicities, with anemia, hypertension, and neutropenia being the predominant adverse effects. While these side effects necessitated dose adjustments in more than half the patients and treatment discontinuation in a fraction, the overall tolerability of pralsetinib remained favorable. Notably, three patient deaths were attributed to treatment-related causes, highlighting the imperative for vigilant monitoring and supportive care. Importantly, unlike other RET inhibitors, pralsetinib did not provoke hypersensitivity reactions in patients previously treated with immunotherapies, a critical consideration given the expanding landscape of immuno-oncology.
The implications of this study extend beyond mere numbers. According to Dr. Justin Gainor, an expert in solid tumor oncology and senior author of the research, the prolongation of median overall survival to approximately 44 months signals a monumental leap forward for RET fusion-positive NSCLC patients. This outcome reflects not only pralsetinib’s potent antitumor efficacy but also the vital importance of early and comprehensive biomarker testing in clinical practice. Detecting RET fusions early can decisively guide personalized treatment choices, potentially transforming patient trajectories with tailored targeted therapies.
Moreover, the research underscores the evolving nature of resistance mechanisms against RET inhibition. Despite pralsetinib’s efficacy, cancer genomes are notoriously plastic, often evolving secondary mutations or activating bypass pathways that undermine therapeutic success over time. The identification and characterization of these resistance patterns remain a crucial frontier, enabling next-generation inhibitors and combination regimens to be developed, thereby sustaining durable remissions and potentially eradicating minimal residual disease.
The ARROW study’s methodology, encompassing an open-label, multi-center phase 1/2 design with a prolonged follow-up, provides a robust clinical framework. Such comprehensive data capture over an extended period allows for the nuanced assessment of both efficacy endpoints and adverse event profiles. This approach contrasts with short-term studies that may overlook chronic treatment effects or late-emerging toxicities, thus reinforcing the credibility and clinical relevance of the reported findings.
This groundbreaking work was the culmination of collaborative efforts from a multinational team of oncology specialists, including renowned figures such as Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano, and others from leading institutions. Their collective expertise spans molecular oncology, clinical trial design, and cancer genomics, reflecting the multidisciplinary synergy required to tackle complex oncogenic drivers. The authorship also includes representatives affiliated with pharmaceutical industry partners, underscoring the critical role of industry-academia partnerships in drug development.
Looking forward, these findings invigorate the oncology community’s commitment to refining RET-targeted therapies and underscore the merit in exploring pralsetinib’s potential across other RET-driven malignancies. As precision oncology continues to evolve, integrating comprehensive genomic profiling with innovative targeted agents offers the promise of transforming cancer management from a one-size-fits-all model to a highly individualized and effective therapeutic strategy. Ultimately, patients facing the daunting diagnosis of RET fusion-positive NSCLC can now hold renewed hope for improved survival and quality of life thanks to such scientific advancements.
Subject of Research: People
Article Title: Final Efficacy and Safety Data From the Phase 1/2 ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
News Publication Date: 27-Mar-2026
Web References:
Journal of Clinical Oncology DOI: 10.1200/JCO-25-01489
References:
Besse B et al. “Final Efficacy and Safety Data From the Phase 1/2 ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).” Journal of Clinical Oncology, DOI: 10.1200/JCO-25-01489.
Keywords:
RET fusion, non-small cell lung cancer, pralsetinib, targeted therapy, phase 1/2 clinical trial, ARROW study, lung cancer treatment, personalized oncology, brain metastases, RET inhibitors, fusion partners, cancer genomics
Tags: advanced RET fusion-positive NSCLCARROW clinical trial resultsbrain metastases in lung cancerFDA-approved RET inhibitorslong-term survival in lung cancernon-small cell lung cancer targeted therapynovel treatments for rare lung cancer mutationspersonalized medicine in oncologypralsetinib in NSCLCRET gene fusion lung cancer treatmentRET kinase inhibitors for cancertargeted therapies for lung cancer
